Reckitt Earnings Call: Growth Engines vs. Headwinds

Reckitt ((GB:RKT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Reckitt’s latest earnings call struck a cautiously upbeat tone, as strong growth in Emerging Markets, expanding margins and rising shareholder returns offset visible regional and category headwinds. Management stressed confidence in its cost-saving and investment programs, even as Europe, seasonal OTC weakness and near‑term EPS pressure temper the otherwise positive operational story.

Core Revenue Growth Remains Solid Despite OTC Drag

Core Reckitt like‑for‑like net revenue grew 5.2% in 2025, with 1.5% volume growth and 3.7% price and mix, while group net revenue rose 5.0%. Excluding the softer seasonal OTC portfolio, Core Reckitt delivered a more robust 7.0% year‑on‑year increase, underscoring underlying demand across its key categories.

Emerging Markets Power the Top Line

Emerging Markets were the clear growth engine, with Core Reckitt EM revenue up 14.6% and volumes up 6.7%. China posted its tenth consecutive quarter of double‑digit gains and India grew at a high single‑digit rate, while several smaller markets delivered double‑digit increases, broadening the growth base.

Margins Expand as Profitability Improves

Core Reckitt’s adjusted operating margin expanded by 90 basis points, with the group margin up 40 basis points to 24.9%. Emerging Markets profitability was a standout, with adjusted operating margin improving 210 basis points to 20.9%, helping group adjusted operating profit grow about 5.3% at constant currency.

Innovation Pipeline Underpins Brand Momentum

Management highlighted a series of product wins, from Durex Intensity now in 18 countries to new Lysol, Dettol, Nurofen mini liquid caps and Strepsils dual‑action formats. Mucinex 12‑hour Cold & Fever was called out as a rare breakthrough in U.S. upper respiratory care, being the first FDA‑approved new drug application in the category in over 15 years.

Fuel for Growth Program Drives Cost Savings

The Fuel for Growth efficiency program delivered 150 basis points of fixed‑cost savings in 2025 and funded a 120 basis‑point increase in brand equity investment. Group fixed costs fell to 19.4% of net revenue and management now aims to exit 2027 with fixed costs below 19%, reinforcing margin resilience over the medium term.

Portfolio Simplification Sharpens Strategic Focus

Reckitt completed the sale of its Essential Home business to Advent in December 2025, returning the proceeds to investors via an additional special dividend in early 2026. The transaction leaves the company focused on 11 high‑growth power brands, a tighter portfolio that management believes will support faster, more disciplined execution.

Shareholder Returns Stay Front and Centre

In 2025, Reckitt returned £2.3bn to shareholders through dividends and share buybacks, including £900m of repurchases. Management signalled that ongoing buybacks will remain a key part of capital allocation, complementing a progressive dividend and reinforcing the company’s commitment to cash returns.

Supply Chain Investments Start to Pay Off

Capital expenditure increased to £592m as Reckitt accelerated the localisation, automation and digitalisation of its supply chain. New Durex lines in Taicang, progress at the Wilson factory in North Carolina and expanded Lysol and Finish capacity have already supported better service levels across Europe and North America.

Europe Struggles Amid Weak Categories and Promotions

Europe was a soft spot, with net revenue down 1.4% and volumes down 3.1% for the year as overall category growth slowed to roughly flat. Rising promotional intensity squeezed both growth and market share, leaving the region as a drag on the otherwise healthy group performance.

Seasonal OTC Weakness Weighs on Shares

Seasonal OTC revenues declined mid‑single digits in 2025, contributing to market share pressure in several large country‑market units. Management noted that only 51% of top CMUs were in gain or hold territory, with Mucinex in particular losing share as it lapped a weak cold‑and‑flu season.

North America Faces Margin and Mix Challenges

North America revenue was essentially flat, up just 0.2% like‑for‑like for the year, reflecting mixed category trends. Adjusted operating margin slipped around 30 basis points to 30.1% as gross margin came under pressure from less favourable category mix, even though nonseasonal brands continued to perform well.

Cash Flow Strong but Leverage Set to Rise Temporarily

Free cash flow reached £1.7bn in 2025 with a 71% conversion rate, although this marked some softening versus prior years. Net debt to adjusted EBITDA ended at 1.6 times, but management acknowledged that leverage is likely to increase toward about 2.5 times by the first half of 2026 before gradually declining thereafter.

Stranded Costs Cloud 2026 Margin Outlook

The Essential Home divestment leaves behind stranded costs that will pressure fixed‑cost ratios in 2026. Reckitt expects the Fuel for Growth program to largely offset these headwinds during the year, but warned that margins could temporarily tick up in 2026 before improving again into 2027 as savings fully land.

EPS Growth Modest Amid Tax and FX Headwinds

Adjusted diluted EPS edged up only 1.1% to 352.8p in 2025, despite healthy operational progress, as a higher effective tax rate and adverse foreign exchange shaved roughly 7% from earnings. Management also flagged dilution headwinds in 2026 tied to the Essential Home divestment, which will partially offset other EPS supports.

Higher Tax Rate Becomes a Structural Drag

Reckitt guided to an effective tax rate of around 27% for 2026, up from an unusually low level in 2024, which will act as an ongoing earnings headwind versus that easy base. The company has hedged about 55% of its foreign exchange and commodity exposure over a 12‑month horizon to reduce volatility on top of the higher tax load.

Mead Johnson’s Strategic Future Remains Open

Mead Johnson Nutrition grew a modest 3.8% in 2025 and is expected to grow at a low single‑digit pace in 2026. However, management continues to review all strategic options for the business, and near‑term guidance includes a mid‑single‑digit revenue decline in the first quarter as it laps last year’s retailer inventory rebuild.

Guidance Points to Steady Growth and Margin Discipline

For 2026, Reckitt expects Core like‑for‑like net revenue to grow 4% to 5%, in line with its medium‑term ambition, although first‑quarter growth should run below the full‑year pace. The group aims to largely offset stranded costs and keep margins broadly intact, while holding CapEx around 4% of revenue, maintaining free cash flow near 2025 levels and letting leverage peak in mid‑2026 before easing.

Reckitt’s earnings call painted a picture of a business with strong growth engines and improving margins but also clear near‑term challenges in Europe, seasonal categories and earnings translation. For investors, the story hinges on whether Emerging Markets momentum, innovation and Fuel for Growth savings can continue to outweigh regional softness and temporary financial headwinds over the next two years.